Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2668
http://purl.obolibrary.org/obo/NCIT_C2668
|
|---|---|
| Preferred Name | Lenalidomide |
| Definitions |
A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. |
|---|---|
| prefLabel | Lenalidomide
|
| label | Lenalidomide
|
| CHEBI_ID | CHEBI:63791
|
| PDQ_Closed_Trial_Search_ID | 38564
|
| code | C2668
|
| Has_Target | |
| prefixIRI | NCIT:C2668
|
| in_subset |
See more
See less
|
| Display_Name | Lenalidomide
|
| Preferred_Name | Lenalidomide
|
| FDA_UNII_Code | F0P408N6V4
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C13H13N3O3
|
| Maps_To | Lenalidomide
|
| CAS_Registry | 191732-72-6
|
| NSC Number | 703813
|
| NCI_Drug_Dictionary_ID | 38564
|
| Legacy Concept Name | CC-5013
|
| PubMedID_Primary_Reference | 16085014
|
| type | |
| ALT_DEFINITION | A drug that is similar to thalidomide, and is used to treat multiple myeloma and certain types of anemia. It is also being studied in the treatment of other types of cancer. Lenalidomide belongs to the family of drugs called angiogenesis inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38564
|
| Accepted_Therapeutic_Use_For | Transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndrome; multiple myeloma, lymphoma
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1144149
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |